$BBIO News

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?

BridgeBio Pharma Files Prospectus Related To Offer And Sale Of Up To 24.6M Common Shares By Selling Stockholders

FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

BridgeBio Pharma Announces FDA Accepts For Filing Its New Drug Application For Encaleret To Treat Autosomal Dominant Hypocalcemia Type 1

Citigroup Maintains Neutral on BridgeBio Pharma, Raises Price Target to $93

HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $120

BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma (BBIO) Is Up 16.8% After Phase 3 Infigratinib Win And $934M Raise

BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?

BridgeBio stock jumps after rival heart drug fails key trial

BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’

Is BridgeBio Pharma (BBIO) Trading At A Premium Already?

BridgeBio Announces Publication Of New Analyses In Circulation: Heart Failure, Examining Kidney Function In Individuals With Transthyretin Amyloid Cardiomyopathy Treated With Acoramidis

BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish

Reported Sunday, BridgeBio PROPEL 3 Phase 3 Trial Published In NEJM, Oral Infigratinib Demonstrates Statistically Significant Improvements In Height, Body Proportionality In Achondroplasia

BridgeBio Pharma To Share Additional Data From PROPEL 3, Its Phase 3 Pivotal Study Of Oral Infigratinib In Children Living With Achondroplasia, In A Late Breaking Oral Presentation At The International Congress Of Children’s Bone Health, June 27-30

Mizuho Maintains Outperform on BridgeBio Pharma, Lowers Price Target to $96

Canaccord Genuity Initiates Coverage On BridgeBio Pharma with Buy Rating, Announces Price Target of $104